Although the tumor-associated antigen MUCl could be a potential target molecule for a protective immune response against MUC1-expressing carcinoma cells, tumors are not normally rejected by the host's immune system, despite the fact that MUC1-specific CTLs have been detected in cancer patients. The gene discussed is MUC1; the disease is carcinoma.